Abstract
The paper aims to briefly describe the pharmacotherapy of inflammatory rheumatic diseases. The goal of pharmacotherapy is to affect the underlying intammatory and immunopathological processes to achieve remission or Iow diseaseactivity with a decrease In the clinical and laboratory activity ofthe di-sease, slowing down or stopping radioiogical structural progression and associated functional dechne (disability).
Such disease-modifying effect Is associated wlth the use of basal disease-modifying antirheumatic drugs (DMARDs).The term has been used to indicate drugs that reciuce the rate of damage to bone and cartilage but in combination with corticosteroids they are aiso able to influence the organ complications of rheumatic diseases DMARDs can be further sub divided into conventional drugs synthesized chemicahly (csDMARDs) and newer biological agents produced through genetic engineering (bo DMARDs) This paper is focused mainly on pharmacological treatment Of rheumatic diseases with coriventional DMARDS (hydroxychloroquine methotrexate lellunomide and others) glucocorricoids and nonsteroidal infiammatorv drugs